Pfizer Inc. $PFE Holdings Lifted by QSM Asset Management Ltd

Key Points

• QSM Asset Management increased its Pfizer stake by 13.8% in the second quarter to 559,438 shares valued at approximately $13.5 million. Pfizer now represents 7% of QSM’s portfolio, while institutional investors collectively own 68.36% of the company.
• Analysts maintain a broadly cautious outlook, with a consensus “Hold” rating and a $28.28 price target. Pfizer shares opened at $26.77, near the middle of their 52-week range.
• Pfizer exceeded quarterly expectations with adjusted EPS of $0.77 and revenue of $15.03 billion, while declaring a $0.43 quarterly dividend yielding about 6.4%. Investors remain focused on declining post-COVID revenue and pipeline execution risks.

QSM Asset Management Ltd boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 13.8% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 559,438 shares of the biopharmaceutical company's stock after purchasing an additional 67,800 shares during the period. Pfizer comprises 7.0% of QSM Asset Management Ltd's investment portfolio, making the stock its 2nd biggest position. QSM Asset Management Ltd's holdings in Pfizer were worth $13,471,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. Vermillion Wealth Management Inc. grew its holdings in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock valued at $66,000 after acquiring an additional 382 shares in the last quarter. Eagle Capital Management LLC lifted its holdings in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after acquiring an additional 390 shares during the period. Delta Financial Advisors LLC lifted its holdings in Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock worth $709,000 after acquiring an additional 398 shares during the period. Pines Wealth Management LLC boosted its position in Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company's stock worth $235,000 after purchasing an additional 400 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD boosted its position in Pfizer by 1.0% in the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company's stock worth $1,177,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PFE. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. Finally, HSBC lowered shares of Pfizer from a "buy" rating to a "hold" rating and decreased their price target for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Trading Down 0.1%

Shares of PFE opened at $26.77 on Friday. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The business has a 50-day moving average of $25.12 and a 200 day moving average of $26.20. The firm has a market cap of $152.60 billion, a P/E ratio of 35.23 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio is presently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source